Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells

Human Gene Therapy

Volumn 10, Issue 8, 1999, Pages 1321-1329

  Medin, Jeffrey A ^a   Takenaka, Toshihiro ^b   Carpentier, Stephane ^c   Garcia, Virginie ^c   Basile, Jean Pierre ^c   Segui, Bruno ^c   Andrieu Abadie, Nathalie ^c   Auge, Nathalie ^c   Salvayre, Robert ^c   Levade, Thierry ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLSPHINGOSINE DEACYLASE; CERAMIDE; COMPLEMENTARY DNA; SOMATOMEDIN B RECEPTOR; VIRUS VECTOR;

ARTICLE; CATABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; FARBER DISEASE; FIBROBLAST; GENE TRANSFER; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; RETROVIRUS; VIRUS RECOMBINANT;

AMIDOHYDROLASES; CELL LINE, TRANSFORMED; CELLS, CULTURED; DNA, COMPLEMENTARY; FIBROBLASTS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; LYSOSOMAL STORAGE DISEASES; RECOMBINATION, GENETIC; RETROVIRIDAE;

UNIDENTIFIED RETROVIRUS;

EID: 0033587181     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018003     Document Type: Article

References (44)

1. AL, B.J.M., TIFFANY, C.W., GOMES DE MESQUITA, D., MOSER, H.W., TAGER, J.M., and SCHRAM, A.W. (1989). Properties of acid ceramidase from human spleen. Biochim. Biophys. Acta 1004, 245-251.
2. BERNARDO, K., HURWITZ, R., ZENK, T., DESNICK, R.J., FERLINZ, K., SCHUCHMAN, E.H., and SANDHOFF, K. (1995). Purification, characterization, and biosynthesis of human acid ceramidase. J. Biol. Chem. 270, 11098-11102.
3. CHATELUT M., FEUNTEUN, J., HARZER, K., FENSOM, A.H., BASILE, J.P., SALVAYRE, R., and LEVADE, T. (1996). A simple method for screening for Farber disease on cultured skin fibroblasts. Clin. Chim. Acta 245, 61-71.
4. CHATELUT, M., HARZER, K., CHRISTOMANOU, H., FEUNTEUN, J., PIERAGGI, M.T., PATON, B., KISHIMOTO, Y., O'BRIEN, J., BASILE, J.P., THIERS, J.C., SALVAYRE, R., and LEVADE, T. (1997). Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies. Clin. Chim. Acta 262, 61-76.
5. CHATELUT, M., LERUTH, M., HARZER, K., DAGAN, A., MARCHESINI, S., GATT, S., SALVAYRE, R., COURTOY, P., and LEVADE, T. (1998). Natural ceramide is unable to escape the lysosome, in contrast to a fluorescent analogue. FEBS Lett. 426, 102-106.
6. CORRELL, P., COLILLA, S., and KARLSSON, S. (1994). Retroviral vector design for long-term expression in murine hematopoietic cells in vivo. Blood 84, 1812-1822.
7. DULANEY, J.T., and MOSER, H.W. (1977). Farber disease (lipogranulomatosis). In Practical Enzymology of the Sphingolipidoses. R.H. Glew and S.P. Peters, eds. (Alan R. Liss, New York) pp. 283-296.
8. FENSOM, A.H., BENSON, P.P., NEVILLE, B.R.G., MOSER, H.W., MOSER, A.B., and DULANEY, J.T. (1979). The prenatal diagnosis of Farber's disease. Lancet 2, 990-992.
9. FILLAT, C., SIMONARO, C.M., YEYATI, P.L., ABKOWITZ, J.L., HASKINS, M.E., and SCHUCHMAN, E.H. (1996). Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. J. Clin. Invest. 98, 497-502.
10. FOLCH, J., LEES, M., and SLOANE-STANLEY, G.H. (1957). A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497-509.
11. GATT, S. (1963). Enzymic hydrolysis and synthesis of ceramides. J. Biol. Chem. 238, 3131-3133.
12. GRABER, D., SALVAYRE, R., and LEVADE, T. (1994). Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of effective residual lysosomal sphingomyelinase activity in intact cells. J. Neurochem. 63, 1060-1068.
13. HAKOMORI, S. (1990). Bifunctional role of glycosphingolipids. J. Biol. Chem. 265, 18713-18716.
14. HANNUN, Y.A. (1994). The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269, 3125-3128.
15. HANNUN, Y.A. (1996). Functions of ceramide in coordinating cellular responses to stress. Science 274, 1855-1859.
16. HOOGERBRUGGE, P.M., BROUWER, O.F., BORDIGONI, P., RINGDEN, O., KAPAUN, P., ORTEGA, J.J., O'MEARA, A., CORNU, G., SOUILLET, G., FRAPPAZ, D., BLANCHE, S., and FISCHER, A. (1995). Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 345, 1398-1402.
17. KISIC, A., and RAPPORT, M.M. (1974). Determination of long-chain base in glycosphingolipids with fluorescamine. J. Lipid Res. 15, 179-180.
18. KOCH, J., GÄRTNER, S., LI, C.M., QUINTERN, L.E., BERNARDO, K., LEVRAN, O., SCHNABEL, D., DESNICK, R.J., SCHUCHMAN, E.H., and SANDHOFF, K. (1996). Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. J. Biol. Chem. 271, 33110-33115.
19. KOLESNICK, R.N. (1991). Sphingomyelin and derivatives as cellular signals. Prog. Lipid Res. 30, 1-38.
20. KORNFELD, S. (1987). Trafficking of lysosomal enzymes. FASEB J. 1, 462-468.
21. KRIVIT, W., and SHAPIRO, E.G. (1994). Bone marrow transplantation for storage diseases. In Bone Marrow Transplantation. S.J. Forman, K.G. Blume, and E.D. Thomas, eds. (Blackwell Scientific Publications, Boston, MA) pp. 883-891.
22. LEVADE, T., ENDERS, H., SCHLIEPHACKE, M., and HARZER, K. (1995a). A family with combined Farber and Sandhoff, isolated Sandhoff and isolated fetal Farber disease: Postnatal exclusion and prenatal diagnosis of Farber disease using lipid loading tests on intact cultured cells. Eur. J. Pediatr. 154, 643-648.
23. LEVADE, T., MOSER, H.W., FENSOM, A.H., HARZER, K., MOSER, A.B., and SALVAYRE, R. (1995b). Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells. J. Neurol. Sci. 134, 108-114.
24. LEVADE, T., LERUTH, M., GRABER, D., MOISAND, A., VERMEERSCH, S., SALVAYRE, R., and COURTOY, P. (1996). In situ assay of acid sphingomyelinase and ceramidase based on LDL-mediated lysosomal targeting of ceramide-labeled sphingomyelin. J. Lipid Res. 37, 2525-2538.
25. MARKOWITZ, D., GOFF, S., and BANK, A. (1988). Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400-406.
26. MEDIN, J.A., MIGITA, M., PAWLIUK, R., JACOBSON, S., AMIRI, M., KLUEPFEL-STAHL, S., BRADY, R.O., HUMPHRIES, R.K., and KARLSSON, S. (1996a). A bicistronic therapeutic retroviral vector enables sorting of transduced CD34+ cells and corrects the enzyme deficiency in cells from Gaucher patients. Blood 87, 1754-1762.
27. MEDIN, J.A., TUDOR, M., SIMOVITCH, R., QUIRK, J.M., JACOBSON, S., MURRAY, G.J., and BRADY, R.O. (1996b). Correction in trans for Fabry disease: Expression, secretion, and uptake of α-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc. Natl. Acad. Sci. U.S.A. 93, 7917-7922.
28. MEDIN, J.A., RICHTER, J., and KARLSSON, S. (1998). Clinical applications of gene therapy: Correction of genetic disease affecting hematopoietic cells. In Stem Cell Biology and Gene Therapy. P.J. Quesenberry, G.S. Stein, B. Forget, and S. Weissman, eds. (Wiley-Liss, New York) pp. 363-384.
29. MERRILL, A.H., and JONES, D.D. (1990). An update of the enzymology and regulation of sphingomyelin metabolism. Biochim. Biophys. Acta 1044, 1-12.
30. MOMOI, T., BEN-YOSEPH, Y., and NADLER, H.L. (1982). Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls. Biochem. J. 205, 419-425.
31. MORITZ, T., KELLER, D.C., and WILLIAMS, D.A. (1993). Human cord blood cells as targets for gene transfer: Potential use in genetic therapies of severe combined immunodeficiency disease. J. Exp. Med. 178, 529-536.
32. MOSER, H.W. (1995). Ceramidase deficiency: Farber lipogranulomatosis. In The Metabolic and Molecular Bases of Inherited Disease. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, eds. (MeGraw-Hill, New York) pp. 2589-2599.
33. MOULLIER, P., BOHL, D., HEARD, J.M., and DANOS, O. (1993). Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nature Genet. 4, 154-159.
34. MOULLIER, P., BOHL., D., CARDOSO, J., HEART, J.M., and DANOS, O. (1995). Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs. Nature Med. 1, 353-357.
35. NOWACZYK, M.J., FEIGENBAUM, A., SILVER, M.M., CALLAHAN, J., LEVIN, A., and JAY, V. (1996). Bone marrow involvement and obstructive jaundice in Farner lipogranulomatosis: Clinical and autopsy report of a new case. J. Inher. Metab. Dis. 19, 655-660.
36. RIBONI, L., VIANI, P., BASSI, R., PRINETTI, A., and TETTAMANTI, G. (1997). The role of sphingolipids in the process of signal transduction. Prog. Lipid Res. 36, 153-195.
37. SAMBROOK, J., FRITSCH, E.F., and MANIATIS, T. (1989). Molecular Cloning: A Laboratory Manual. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
38. SMITH, P.K., KROHN, R.I., HERMANSON, G.T., MALLIA, A.K., GARTNER, F.H., PROVENZANO, M.D., FUJIMOTO, E.K., GOEKE, M.N., OLSON, B.J., and KLENK, D.C. (1985). Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
39. SOUILLET, G., GUIBAUD, P., FENSOM, A.H., MAIRE, I., and ZABOT, M.T. (1989). Outcome of displacement bone marrow transplantation in Farber's disease: A report of a case. In The Correction of Certain Genetic Diseases by Transplantation. J.R. Hobbs, ed. (Cogent Press, London) pp. 137-141.
40. SPIEGEL, S., FOSTER, D., and KOLESNICK, R.N. (1996). Signal transduction through lipid second messengers. Curr. Opin. Cell Biol. 8, 159-167.
41. SUGITA, M., DULANEY, J.T., and MOSER, H.W. (1972). Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science 178, 1100-1102.
42. TAYLOR, R.M., and WOLFE, J.H. (1997). Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of β-glucuronidase. Nature Med. 3, 771-774.
43. VAN VELDHOVEN, P.P., MATTHEWS, T.J., BOLOGNESI, D.P., and BELL, R.M. (1992). Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells. Biochem. Biophys. Res. Commun. 187, 209-216.
44. WOLFE, J.H., SANDS, M.S., BARKER, J.E., GWYNN, B., ROWE, L.B., VOLGER, C.A., and BIRKENMEIER, E.H. (1992). Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature (London) 360, 749-753.